Takeda Pharmaceutical said on August 16 that it has earned Japanese regulatory approval for an additional 0.5 mg capsule version of its multiple myeloma (MM) drug Ninlaro (ixazomib). The new version, which comes on top of the existing 2.3 mg,…
To read the full story
Related Article
- Takeda’s Fruzaqla Now Available in Japan, AbbVie’s Skyrizi Adds New Version
November 25, 2024
- Takeda Files Low-Dose Form of Ninlaro in Japan
September 25, 2023
BUSINESS
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





